{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\u26a1 Beyond Carbapenems: The Nacubactam Revolution in complicated UTI","description":"\ud83e\udda0 The INTEGRAL-1 trial in The Lancet delivers exciting data for resistant urinary tract infections. Cefepime\u2013nacubactam achieved both noninferiority AND superiority vs imipenem\u2013cilastatin in complicated UTI and acute pyelonephritis. &amp;nbsp; \u26a1 Strong microbiological eradication, promising ESBL activity, and favorable safety profiles suggest an important future role in carbapenem-sparing strategies. &amp;nbsp; #UTI #Lancet #AntimicrobialResistance #ESBL #InfectiousDiseases #MedicalPodcasts ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41374490\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202180010"}